In 2025, the company's Cushing's syndrome business experienced a surge in demand with record new prescriptions and new prescribers, translating to a 37 percent increase in tablets sold compared to the prior year. The company has a large portfolio of proprietary compounds that selectively modulate the effects of cortisol but not progesterone, backed by extensive intellectual property.
Cyborg Score Rationale
Commercial success with Korlym generating $761.4M in 2025 revenue, strong execution reflected in 37% tablet volume growth, profitability with $99.7M net income, and multiple clinical-stage programs (ALS, liver disease, solid tumors). Challenges include prior specialty pharmacy constraints and competitive pharmaceutical landscape.
Top Insights
2025 marked breakout commercial year for Korlym with surge in physician recognition of hypercortisolism prevalence, driving record prescriptions and new prescriber additions
Supply chain constraints at previous specialty pharmacy vendor created artificial ceiling on growth; transition to new vendor now complete and February 2026 tracking as record month for new patients
Dazucorilant showing promising Phase 2 results in ALS with profound reduction in early mortality; advancing dose titration studies for Phase 3
Miricorilant in Phase 2b MONARCH trial for metabolic dysfunction-associated steatohepatitis with topline results expected by end of 2026
Named Competitors
Vanda Pharmaceuticals — Biopharmaceutical company developing treatments for neurological and psychiatric disorders
Axsome Therapeutics — Clinical-stage biopharmaceutical company focused on neurological and psychiatric disorders
Sarepta Therapeutics — Biopharmaceutical company developing gene therapy and other treatments for serious rare diseases
Recent Developments
(February 2026) Fourth quarter and full year 2025 results: Revenue $761.4M (+12.8% YoY), net income $99.7M; announced dazucorilant Phase 2 mortality benefits in ALS
(November 2025) Third quarter results: Revenue $207.6M, record prescriptions and prescriber additions; enrolled MONARCH Phase 2b trial for miricorilant
(February 2026) Completed transition to new specialty pharmacy vendor; February tracking as record month for new patient starts
Open the full interactive Corcept Therapeutics Incorporated report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.